Sign inJoin waitlistJoin the waitlist

Kenneth Byrd

Associate Professor, Hematologic Malignancies and Cellular Therapeutics · University of Kansas School of Medicine

Credentials: · · · · ·

History

University of Kansas School of Medicine
Present

Hematology and Medical Oncology
The University of Tennessee Health Science Center
2015–2018
Internal Medicine
University of Kansas School of Medicine
2012–2015
Kansas City University
2008–2012

Research

Using fixed anatomical landmarks in endoscopic skull base surgery
American Journal of Rhinology and Allergy · 2010 · 29 citations
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
Journal of Clinical Oncology · 2025 · 9 citations
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute…
Systematic review or meta-analysis · Clinical Lymphoma · 2023 · 9 citations

Heather Male
3 papers
Aaron Logan
2 papers
Anjali Advani
2 papers
BS
Bijal Shah
2 papers
Caspian Oliai
2 papers
Catherine Lee
2 papers
Chenyu Lin
2 papers
Eunice Wang
2 papers
George Yaghmour
2 papers
Gregory Roloff
2 papers
HS
Hrishi Srinagesh
2 papers · 2 as a fellow
Ibrahim Aldoss
2 papers

Clinical trials

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2017–2027